Overview
Our laboratory is interested in understanding the molecular and genetic events underlying cancer progression and metastasis. The focus of our work is a series of genetically engineered mouse models that faithfully recapitulate human disease. Using a combination of mouse genetics, omics technologies, cross-species analyses and in vitro approaches, we aim to identify cancer cell–intrinsic and –extrinsic mechanisms driving metastatic cancer progression, with a long–term goal of developing new therapeutic strategies for preventing and treating metastatic disease.
Current Appointments & Affiliations
Associate Professor of Pathology
·
2025 - Present
Pathology,
Clinical Science Departments
Associate Research Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation.
Journal Article Oncogene · November 2025 Lipid metabolism is among the most frequently dysregulated metabolic processes in human cancer, yet how cellular lipids, the end products of lipogenesis, and their composition are altered to support various aspects of cancer remains poorly understood. Here ... Full text Open Access Link to item CiteComparative analysis of gene regulation in single cells using Compass.
Journal Article Cell Rep Methods · May 19, 2025 Single-cell multi-omics is a transformative technology that measures both gene expression and chromatin accessibility in individual cells. However, most studies concentrate on a single tissue and are unable to determine whether a gene is regulated by a cis ... Full text Open Access Link to item CiteVaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.
Journal Article Vaccines (Basel) · November 13, 2024 Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target thi ... Full text Link to item CiteRecent Grants
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology for Prostate Cancer
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027View All Grants
Education, Training & Certifications
University of Rochester ·
2009
Ph.D.